Chimerix (NASDAQ:CMRX - Get Free Report)'s stock had its "outperform" rating restated by equities research analysts at Wedbush in a note issued to investors on Monday, Marketbeat Ratings reports. They currently have a $6.00 price objective on the biopharmaceutical company's stock.
CMRX has been the subject of a number of other research reports. StockNews.com upgraded shares of Chimerix from a "sell" rating to a "hold" rating in a report on Wednesday, August 21st. HC Wainwright reissued a "buy" rating and issued a $11.00 price objective on shares of Chimerix in a research note on Monday, November 11th.
Check Out Our Latest Research Report on CMRX
Chimerix Stock Up 2.3 %
NASDAQ CMRX traded up $0.02 on Monday, hitting $0.88. 186,991 shares of the stock were exchanged, compared to its average volume of 354,376. The company has a 50-day moving average price of $0.90 and a 200-day moving average price of $0.91. Chimerix has a fifty-two week low of $0.75 and a fifty-two week high of $1.30. The company has a market cap of $79.14 million, a PE ratio of -0.94 and a beta of 1.13.
Institutional Trading of Chimerix
A number of hedge funds have recently bought and sold shares of the company. Valeo Financial Advisors LLC increased its holdings in Chimerix by 566.9% in the third quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company's stock worth $76,000 after buying an additional 69,505 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its position in Chimerix by 66.8% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company's stock worth $321,000 after purchasing an additional 138,098 shares during the period. Marshall Wace LLP bought a new position in Chimerix in the second quarter worth $137,000. Finally, Acadian Asset Management LLC lifted its position in Chimerix by 15.5% in the first quarter. Acadian Asset Management LLC now owns 2,174,813 shares of the biopharmaceutical company's stock worth $2,304,000 after purchasing an additional 291,981 shares during the period. 45.42% of the stock is owned by hedge funds and other institutional investors.
Chimerix Company Profile
(
Get Free Report)
Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.
Further Reading
Before you consider Chimerix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chimerix wasn't on the list.
While Chimerix currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
